The intrathecal administration of recombinant DcR3–Fc fusion proteins demonstrates a potential therapeutic effect in experimental autoimmune encephalomyelitis, suppresses macrophage activation induced by influenza virus, and mitigates pulmonary inflammation and mortality. The gene discussed is TNFRSF6B; the disease is experimental autoimmune encephalomyelitis.